Sequenom (SQNM) 10-Q 5 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Sep. 30, 2015shares
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Entity Registrant Name	SEQUENOM INC
Entity Central Index Key	1,076,481
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding	118,572,914

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Assets
Cash and cash equivalents	$ 49,665	$ 63,309
Marketable securities, available-for-sale	30,736	30,588
Accounts receivable, net	6,329	9,131
Inventories	4,562	6,516
Other current assets and prepaid expenses	5,345	12,112
Total current assets	96,637	121,656
Property, equipment and leasehold improvements, net	11,209	15,348
Goodwill	10,007	10,007
Intangible assets, net	8,877	11,247
Other assets	1,975	2,813
Total assets	128,705	161,071
Liabilities and stockholders' deficit
Accounts payable	6,423	6,089
Accrued expenses	13,498	22,155
Long-term debt and obligations, current portion	346	4,144
Other current liabilities	634	2,581
Deferred gain on pooled patents agreement	0	21,000
Total current liabilities	20,901	55,969
Long-term debt and obligations, less current portion	5,373	5,602
Convertible senior notes	129,031	130,000
Other long-term liabilities	1,110	664
Total liabilities	$ 156,415	$ 192,235
Commitments and contingencies
Stockholders' deficit:
Convertible preferred stock, par value $0.001; 5,000 shares authorized, no shares issued or outstanding at September 30, 2015 and December 31, 2014	$ 0	$ 0
Common stock, par value $0.001; 185,000 shares authorized, 118,528 and 117,434 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	119	117
Additional paid-in capital	989,539	981,929
Accumulated other comprehensive income	100	87
Accumulated deficit	(1,017,468)	(1,013,297)
Total stockholders' deficit	(27,710)	(31,164)
Total liabilities and stockholders' deficit	$ 128,705	$ 161,071

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Convertible senior notes interest rate	5.00%	5.00%
Convertible preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	185,000,000	185,000,000
Common stock, shares issued	118,527,914	117,434,000
Common stock, shares outstanding	118,527,914	117,434,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues:
Diagnostic services, net	$ 27,688	$ 37,376	$ 94,283	$ 113,475
License	2,213	561	6,190	1,305
Total revenues	29,901	37,937	100,473	114,780
Operating expenses:
Cost of revenues	15,069	21,000	50,971	66,180
Selling and marketing	8,541	7,448	25,386	23,927
Research and development	5,892	6,073	17,413	19,949
General and administrative	8,431	9,457	25,617	36,527
Restructuring costs and other charges	0	0	656	1,885
Total costs and expenses	37,933	43,978	120,043	148,468
Gain (Loss) on Disposition of Assets	750	0	21,750	0
Gain on pooled patents agreement and sale of assets			21,000
Operating income (loss)	(7,282)	(6,041)	2,180	(33,688)
Interest Expense	(2,055)	(2,035)	(6,060)	(6,172)
Interest Expense	19	6	45	11
Other income (expense), net	(41)	(115)	(129)	(173)
Loss from continuing operations before income taxes	(9,359)	(8,185)	(3,964)	(40,022)
Income tax benefit (expense)	(84)	2,107	(207)	8,911
Loss from continuing operations	(9,443)	(6,078)	(4,171)	(31,111)
Discontinued operations:
Earnings from discontinued operations, net of tax	0	0	0	13,812
Net loss	$ (9,443)	$ (6,078)	$ (4,171)	$ (17,299)
Net loss per common share, basic and diluted
Continuing operations	$ (0.08)	$ (0.05)	$ (0.04)	$ (0.27)
Discontinued operations	0	0	0	0.12
Net loss	$ (0.08)	$ (0.05)	$ (0.04)	$ (0.15)
Weighted average number of shares outstanding, basic and diluted	118,432	117,067	118,098	116,516
Statements of Comprehensive Loss
Net loss	$ (9,443)	$ (6,078)	$ (4,171)	$ (17,299)
Other comprehensive income (loss):
Unrealized net gain (loss) on available-for-sale securities, net of taxes	(40)	17	(6)	1
Foreign currency loss on translation adjustment	(6)	0	(7)	0
Total other comprehensive income	(46)	17	(13)	1
Comprehensive loss	$ (9,489)	$ (6,061)	$ (4,184)	$ (17,298)

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating activities
Net loss	$ (4,171)	$ (17,299)
Adjustments to reconcile net loss to net cash used in operating activities:
Earnings from discontinued operations, net of tax	0	(13,812)
Share-based compensation	5,465	9,091
Depreciation and amortization	8,049	9,247
Non-cash restructuring costs and other charges	386	1,885
Other non-cash items	925	143
Gain on pooled patents agreement and sale of assets	(21,723)	0
Changes in operating assets and liabilities:
Accounts receivable	2,801	(4,040)
Inventories	1,954	5,608
Prepaid expenses and other assets	336	250
Accounts payable and accrued expenses	(8,546)	(4,074)
Other liabilities	(1,500)	(9,341)
Net cash used in operating activities of continuing operations	(16,024)	(22,342)
Investing activities
Purchases of property, equipment and leasehold improvements	(1,691)	(1,007)
Purchases of marketable securities	(20,150)	(40,149)
Maturities of marketable securities	20,000	19,169
Net cash received from sale of segment	0	29,291
Proceeds from pooled patents agreement	6,000	0
Proceeds from sale of assets	750	0
Change in restricted cash	(500)	0
Net cash provided by investing activities of continuing operations	5,409	7,304
Financing activities
Payments on term loan and capital lease obligations	(4,042)	(5,641)
Proceeds from common stock issued under employee stock plans	1,046	1,777
Net cash used in financing activities of continuing operations	(2,996)	(3,864)
Net cash provided by operating activities of discontinued operations	0	2,816
Net cash used in investing activities of discontinued operations	0	(164)
Net cash provided by discontinued operations	0	2,652
Effect of exchange rate changes on cash and cash equivalents	(33)	0
Net decrease in cash and cash equivalents	(13,644)	(16,250)
Cash and cash equivalents at beginning of period	63,309	61,589
Cash and cash equivalents at end of period	$ 49,665	$ 45,339

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	The Company and a Summary of Its Significant Accounting Policies The Company Sequenom, Inc., and its wholly owned subsidiary Sequenom Center for Molecular Medicine LLC, doing business as Sequenom Laboratories (collectively the "Company"), is a life sciences company committed to enabling healthier lives through the development of innovative products and services. The Company serves patients and physicians by providing early patient management information. The Company develops and commercializes innovative molecular diagnostics testing services that serve the women's health market and is developing products and services for the oncology market. Basis of Presentation and Consolidation The accompanying unaudited condensed consolidated financial statements of Sequenom, Inc. should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 , as filed with the Securities and Exchange Commission. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the interim statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements, which include all wholly owned subsidiaries, reflect all adjustments, consisting of normal recurring adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. Interim results are not necessarily indicative of results for a full year or any other period(s). Reclassifications Certain amounts previously reported have been reclassified to conform to the current period presentation. The reclassification was made to change the statements of operations and comprehensive loss presentation to provide the users of the financial statements additional information related to the revenues of the Company. The reclassification included reclassifying amounts previously included in diagnostic services revenue to license revenue. The reclassification had no effect on consolidated net earnings or consolidated assets and liabilities. Segment and Geographic Information The Company evaluates segment reporting in accordance with Accounting Standards Codification ("ASC") 280 during each reporting period, including evaluating the reporting package reviewed by the Company’s Chief Operating Decision Maker (the "CODM"). As of September 30, 2015, the Company concluded it operates in a single operating segment and a single reporting unit as a provider of innovative diagnostic testing services based on the financial information available and that is evaluated regularly by the CODM in deciding how to allocate resources and in assessing performance. The Company derives its diagnostic services revenue from domestic and international customers by providing testing services in its laboratories located in San Diego, California and Raleigh-Durham, North Carolina. During the three and nine months ended September 30, 2015, 5% of diagnostic services revenue was recognized from international customers. During the three and nine months ended September 30, 2014, 13% of diagnostic services revenue was recognized from international customers. The Company also generates license revenue through the Company's Pooled Patents Agreement (the "Pooled Patents Agreement") with Illumina, Inc. ("Illumina"). The Company has limited visibility into the revenue reported by Illumina to the Company. For the portion of the Company's license revenue recognized from the Pooled Patents Agreement that is derived from Illumina partners or licensees, the Company does not have the ability to determine whether the license revenue was derived from domestic or international sources. Discontinued Operations On May 30, 2014, the Company sold its Bioscience business segment. As a result of the sale, the Company's Bioscience segment has been excluded from continuing operations for all periods herein and reported as discontinued operations. For additional information on the divestiture of the Company's Bioscience segment, see Note 3, Discontinued Operations. Revenue Recognition The Company generates revenue from diagnostic services from providing laboratory-developed tests ("LDTs"), primarily for the detection of specific fetal abnormalities or other genetic conditions, as well as through the Pooled Patents Agreement and others who have licensed the Company's technology. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. The Company assesses whether the fee is fixed or determinable based on the nature of the fee charged for the services delivered, whether there are existing contractual arrangements, and historical payment patterns. In determining when to record revenue, the Company evaluates collectability and considers whether there is sufficient history to reliably estimate a payor's payment patterns. Revenue is deferred for fees received before earned. Diagnostic service revenues are derived from providing testing services in the Company's laboratory, which are reimbursed through arrangements with third-party payors and amounts patients self-pay or through contractual arrangements (client bill). Diagnostic services revenue for third-party payors is recognized upon cash collection until a reliable estimate of the amount that would be ultimately collected for the test and the above criteria have been met, at which time revenue is recognized on an accrual basis. Third-party payors include commercial payors, such as health insurance companies, health maintenance organizations and government payors, such as Medicare and Medicaid in the United States. Client bill revenue is primarily recognized on an accrual basis and includes laboratories and customers with whom the Company has a contractual agreement where they will pay for the test upon delivery of the test results to the ordering physicians. The Company generally bills third-party payors upon delivery of a test result to the ordering physician following completion of a test. Patients have responsibility for out-of-pocket costs for amounts not covered by their insurance carrier and the Company bills the patient directly for these amounts in the form of co-pays and deductibles in accordance with their insurance carrier and health plans. Revenue from patients, through co-payments or through cash based service offerings, are recognized on a cash basis. Some payors may not cover the test as ordered by the physician under their reimbursement policies. Consequently, the Company pursues reimbursement on a case-by-case basis. From time to time, the Company receives requests for refunds of payments, generally due to overpayments made by third-party payors. Upon becoming aware of a refund request, the Company establishes an accrued liability for tests covered by the refund request until such time as the Company determines whether or not a refund is due. License arrangements with third-party partners may involve multiple elements and the Company evaluates the agreements to determine whether each deliverable represents a separate unit of accounting. A deliverable constitutes a separate unit of accounting when it has stand-alone value to the customer. Items are considered to have stand-alone value when they are sold separately by any vendor or when the customer could resell the item on a stand-alone basis. Consideration is allocated at the inception of the contract to all deliverables based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence ("VSOE") of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence exists, the Company uses its best estimate of the selling price for the deliverable. Such amounts are recognized as revenue when each unit is delivered. If the delivered element does not have stand-alone value without one of the undelivered elements in the arrangement, the elements are combined and accounted for as a single unit of accounting. Such amounts are recognized as revenue when the last deliverable of the combined units is delivered. Recurring revenue generated under license or royalty arrangements, including the Pooled Patents Agreement with Illumina, is recognized in the period reported by the partner or licensee and when the revenue recognition criteria have been met. Cost of Revenues Cost of revenues include the cost of materials, direct labor (including laboratory and service personnel), equipment and infrastructure expenses associated with processing blood and other samples, quality control analyses, shipping charges to transport samples, and license and test fees, including those owed to Illumina as specified in the Pooled Patents Agreement. Infrastructure expenses include allocated facility occupancy and information technology costs. Costs associated with performing testing services are recorded as tests are processed. Costs recorded for sample processing and shipping charges represent the cost of all the tests processed during the period regardless of whether revenue is recognized with respect to that test. Royalties for licensed technology calculated on a per test basis or as a percentage of product revenue and fixed annual payments relating to the launch and commercialization of LDTs are recorded as license fees in cost of revenues at the time product revenue is recognized or in accordance with other contractual obligations. Pooled Patents Agreement On December 2, 2014, the Company entered into the Pooled Patents Agreement with Illumina, pursuant to which the parties pooled their intellectual property directed to noninvasive prenatal testing ("NIPT"). In accordance with the Pooled Patents Agreement, Sequenom, Inc. and the Chinese University of Hong Kong ("CUHK") entered into an agreement (the "CUHK Agreement"), pursuant to which certain license agreements by and between the Company and CUHK were amended and assigned to Illumina for inclusion in the patent pool, subject to the Pooled Patents Agreement. Illumina is responsible for paying all royalties to CUHK under the CUHK license agreements, and granted the Company a sublicense under each agreement to exploit laboratory-developed NIPT tests in accordance with the Pooled Patents Agreement. In connection with entering into the Pooled Patents Agreement, the Company also entered into an Amended and Restated Sale and Supply Agreement with Illumina (the "Supply Agreement"), pursuant to which the Company and its affiliates purchase various products from Illumina for use in NIPT as well as for other clinical and research uses. Concurrently, with the execution of the Pooled Patents Agreement, the Company, Illumina, Sequenom Center for Molecular Medicine, LLC ("SCMM" a subsidiary of Sequenom Inc.), and Verinata Health, Inc., (“Verinata ” a subsidiary of Illumina) entered into a Settlement Agreement (the "Settlement Agreement"), pursuant to which the parties settled certain claims and released the other parties from potential liability. The Company determined that the Pooled Patents Agreement, the Settlement Agreement, the Supply Agreement and the CUHK Agreement were all part of a single transaction with multiple elements as the various agreements were contemporaneously negotiated, contingent upon one another and negotiated with the same counterparties. As the agreements were considered to be part of one transaction with multiple elements, the Company followed the accounting guidance in ASC 605-25 to determine the separate units of account and the basis for allocating the consideration received. The Company evaluated all elements of the agreements and identified the following deliverables that had value; (1) the physical samples and applicable study protocols, (2) transfer of in vitro diagnostic, or IVD, technology (3) settlement of claims and disputes between the Company and Illumina and (4) the $6.15 million upfront payment made to CUHK. The Company allocated consideration to the physical samples and transfer of IVD technology based on its best estimate of selling price for each of the deliverables, which were derived from the Company's models as well as through the use of a third-party valuation expert. The physical samples and applicable study protocols were valued using the cost to recreate method, a form of the cost approach. The key inputs and assumptions used in this model included historical clinical study cost for gathering each sample plus a premium applied to the historical costs. The IVD technology was valued using the differential cash flow method, a form of the income approach. The key inputs and assumptions used in this model included forecasted IVD revenues and estimated royalties rates. The Company determined the value to be allocated to the settlement of claims and disputes based on the residual value method due to the complex nature of the litigation and the inability to make a reliable estimate of value for this component. Consideration allocated to each element was $21.0 million for each of (i) the physical samples and (ii) the transfer of IVD technology, and $1.85 million for the settlement of claims and disputes. The $6.15 million payment made by the Company to CUHK was reflected as a reduction of the proceeds received from Illumina as this was primarily for the amendment of certain license agreements by and between the Company and CUHK, and the assignment of those agreements to Illumina for inclusion in the patent pool, and resulted in net consideration to be allocated by the Company of $43.85 million . At December 31, 2014 , the Company had recorded a $21.0 million deferred gain on the Pooled Patents Agreement, which was recognized as a gain during the three months ended March 31, 2015 following delivery and acceptance of the study related documents associated with the physical samples provided to Illumina. Concentration of Risks Financial instruments, which potentially are a concentration of credit risk, consist primarily of cash equivalents, marketable securities, and accounts receivable. The exposure to credit loss is limited by placing cash, cash equivalents and marketable securities with US financial institutions. Additionally, the Company has established guidelines regarding diversification of investments and their maturities, which are designed to maintain principal and maximize liquidity. Credit risk with respect to accounts receivable is limited due to the Company's large and diverse customer base. One customer represented more than 10% of total revenue during the three and nine months ended September 30, 2015, accounting for $3.1 million , or 10.3% , and $10.1 million , or 10.0% , of total revenue, respectively. One customer represented more than 10% of total revenue during the three and nine months ended September 30, 2014, accounting for $4.5 million , or 11.9% , and $17.3 million , or 15.1% , of total revenue, respectively. The Company requires raw materials and devices of appropriate quality and reliability and to meet applicable regulatory requirements that currently are available from a limited number of sources and in certain cases a single source of supply. Consequently, in the event that supplies are delayed or interrupted for any reason, it could impair the Company's ability to develop and produce services, which could have a material adverse effect on the Company's business, financial condition and results of operations. Net Loss Per Share Basic and diluted net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Common stock equivalents that could potentially reduce net earnings per common share in the future that were not included in the determination of diluted net loss per common share as their effects were antidilutive are as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Shares underlying Convertible Senior Notes 28,088 28,088 28,088 28,088 Options to purchase common stock 10,612 12,906 10,510 13,688 Restricted stock units not yet vested and released 2,312 1,877 3,038 2,146 Warrants to purchase common stock 200 250 200 250 Total 41,212 43,121 41,836 44,172 Goodwill The Company accounts for intangible assets in accordance with ASC No. 350, Intangibles-Goodwill and Other (“ASC 350”). The Company reviews goodwill for impairment annually in the fourth quarter and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Goodwill represents the excess of the purchase price in a business combination over the fair value of net tangible and intangible assets acquired. The Company operates as a single reporting unit and considers the Company as a whole when reviewing impairment factors. As the Company has a negative book value, the Company performs a qualitative and quantitative analysis to determine whether it is more likely than not that the fair value of goodwill is less than its carrying amount. Some of the impairment indicators the Company considers include significant differences between the carrying amount and the estimated fair value of our assets and liabilities; macroeconomic conditions such as a deterioration in general economic condition or limitations on accessing capital; industry and market considerations such as a deterioration in the environment in which the Company operates and an increased competitive environment; cost factors such as increases in raw materials, labor, or other costs that have a negative effect on earnings and cash flows; overall financial performance such as negative or declining cash flows or a decline in actual or planned revenue or earnings compared with actual and projected results of relevant prior periods; other relevant events such as litigation, changes in management, key personnel, strategy or customers; the testing for recoverability of our long-lived assets and a sustained decrease in share price. The Company evaluates the significance of identified events and circumstances on the basis of the weight of evidence along with how they could affect the relationship between the reporting unit's fair value and carrying amount, including positive mitigating events and circumstances. If the Company determines it is more likely than not that the fair value of goodwill is less than its carrying amount, then a second step is performed to quantify the amount of goodwill impairment, if any. If an impairment is indicated, a goodwill impairment charge is recorded to write the goodwill down to its implied fair value. During the third quarter of 2015, the Company determined certain indicators of potential impairment were present. Based on this assessment, the Company performed a qualitative and quantitative step one analysis for goodwill impairment. As a result of its analysis, the Company considered the indicators noted above and a comparison of carrying amounts to estimated fair values of the Company’s assets and liabilities. The Company determined it did not meet the more likely than not criteria that the fair value of goodwill was less than its carrying amount, primarily as the fair value of its reporting unit substantially exceeded its carrying value. Therefore step two of the goodwill impairment test was not required. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued an accounting standards update that creates a single source of revenue guidance for companies in all industries. The new standard provides guidance for all revenue arising from contracts with customers and affects all entities that enter into contracts to provide goods or services to their customers, unless the contracts are within the scope of other accounting standards. It also provides a model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets. This guidance, as amended, must be adopted using either a full retrospective approach for all periods presented or a modified retrospective approach and will be effective for fiscal years beginning after December 15, 2017, which will be the Company's fiscal year 2018. The Company has not yet evaluated the potential impact of adopting the guidance on the Company's consolidated financial statements. In April 2015, the FASB issued Accounting Standard Update ("ASU") No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs . The ASU is the result of the FASB's simplification initiative intended to improve GAAP by reducing costs and complexity while maintaining or enhancing the usefulness of related financial statement information. The ASU specifies that debt issuance costs related to a note shall be reported in the balance sheet as a direct reduction from the face amount of the note. The ASU is effective for interim and annual periods beginning on or after January 1, 2016. The ASU will require the Company to reclassify its capitalized debt issuance costs currently recorded as assets on the condensed consolidated balance sheets. The ASU will have no effect on the Company's results of operations or liquidity.

Supplementary Financial Informa

Supplementary Financial Information	9 Months Ended
	Sep. 30, 2015
Other Financial Information [Abstract]
Supplementary Financial Information	Supplementary Financial Information Marketable Securities, Available-for-sale (in thousands): September 30, 2015 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value U.S. treasury securities $ 30,185 $ 9 $ — $ 30,194 Certificates of deposit 50 — — 50 Mutual funds 282 210 — 492 Total marketable securities $ 30,517 $ 219 $ — $ 30,736 December 31, 2014 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value U.S. treasury securities $ 30,049 $ — $ (29 ) $ 30,020 Certificates of deposit 48 — — 48 Mutual funds 277 243 — 520 Total marketable securities $ 30,374 $ 243 $ (29 ) $ 30,588 As of September 30, 2015 and December 31, 2014 , gross unrealized losses on marketable securities were insignificant. There were no impairments considered other-than-temporary for the periods presented, as the Company has the intent and ability to hold the securities for a period of time sufficient to allow for recovery in the market value. As of September 30, 2015 , all marketable securities were due within fifteen months. Other Current Assets and Prepaid Expenses (in thousands): September 30, December 31, Pooled patents agreement receivable $ — $ 6,000 Other 5,345 6,112 Total $ 5,345 $ 12,112 Inventories (in thousands): September 30, December 31, Raw materials $ 4,280 $ 6,165 Work in process 282 351 Total $ 4,562 $ 6,516 Accrued Expenses (in thousands): September 30, December 31, Accrued royalties, licenses, and collaboration payments $ 4,756 $ 7,223 Accrued compensation and related taxes 5,031 7,606 Accrued professional fees and consulting 439 1,872 Other 3,272 5,454 Total $ 13,498 $ 22,155

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2015
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations The results of operations from discontinued operations presented below include certain allocations that management believes fairly reflect the utilization of services provided to the Bioscience business segment. The allocations do not include amounts related to general corporate administrative expenses or interest expense. Therefore, the results of operations from the Bioscience business segment do not necessarily reflect what the results of operations would have been had the business operated as a stand-alone entity. The Company completed the sale of the Biosciences segment on May 30, 2014. Nine Months Ended September 30, Discontinued Operations (in thousands) 2014 Revenues: Bioscience product sales and services $ 12,470 Cost of revenues: Cost of bioscience product sales and services 4,235 Gross margin 8,235 Operating expenses: Selling and marketing 6,237 Research and development 2,248 General and administrative 643 Restructuring costs 19 Total operating expenses 9,147 Loss from discontinued operations (912 ) Other income, net 81 Loss from discontinued operations before income taxes (831 ) Income tax benefit 248 Earnings from discontinued operations $ (583 ) In connection with the sale of the Bioscience segment, the Company also entered into other agreements designed to facilitate the orderly transfer of business operations to the purchaser of the Bioscience business. One agreement is a three year Supply Agreement with the purchaser of the Bioscience business where the Company may purchase consumables and systems for the laboratory business for the first twelve months of the agreement at preferred pricing. Purchases made by the Company of consumables and systems for the three and nine months ended September 30, 2015 were $ 0.2 million and $ 0.5 million , respectively. Purchases made by the Company of consumables and systems for the three and nine months ended September 30, 2014 were $0.3 million and $0.4 million , respectively, and these sales have been eliminated from discontinued operations reported revenue in 2014 because the transaction was intra-entity.

Long-Term Obligations

Long-Term Obligations	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Long-Term Obligations	Long-Term Obligations (in thousands, except percentages): As of September 30, 2015 As of December 31, 2014 5.00% Convertible Senior Notes due October 2017 ($45,000) and January 2018 ($85,000), interest payable semi-annually in April and October $ 130,000 $ 130,000 Unamortized debt discount on Convertible Exchange Senior Notes due January 2018 (969 ) — Bank Loans due May 2015, principal and interest payable monthly, weighted-average effective interest rates of 5.5%, net of unamortized discount of $8 at December 31, 2014. — 3,722 Obligation for building and improvements, effective interest rate of 5.2% as of September 30, 2015 and December 31, 2014, expiring October 2026 5,667 5,868 Capital lease liabilities, expiring January 2016, net of unamortized discounts of $2 and $17 at September 30, 2015 and December 31, 2014, respectively 52 156 Total long-term obligations 134,750 139,746 Less current portion (346 ) (4,144 ) Non-current portion $ 134,404 $ 135,602 Convertible Senior Notes On September 17, 2012 , the Company issued $130 million aggregate principal amount of Convertible Senior Notes (the "2017 Notes") in a private offering to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). On June 4, 2015, the Company entered into separate privately negotiated agreements with certain holders of the 2017 Notes to exchange in a private placement in reliance on Section 4(a)(2) of the Securities Act $85 million in aggregate principal amount of 2017 Notes for $85 million in aggregate principal amount at maturity of new 5.00% Convertible Exchange Senior Notes due 2018 (the "2018 Notes") of the Company (the "Exchange Transactions"). The 2018 Notes were issued on June 9, 2015. The Company accounted for the Exchange Transactions as a debt modification and not a debt extinguishment under ASC 470-50, as the terms of the 2018 Notes were not substantially different from those of the exchanged 2017 Notes. The Company incurred approximately $1.6 million in fees directly related to the Exchange Transactions which were expensed as incurred during the quarter ended June 30, 2015. As noted above, the 2018 Notes term was extended for an additional three months and mature January 1, 2018. The extension of the term increased the fair value of the 2018 Notes embedded, unseparated conversion option by approximately $1.1 million , which was recorded as an increase in the debt discount of the convertible senior notes and corresponding increase in additional paid-in capital and will be amortized over the remaining 30 month term of the 2018 Notes using the effective interest rate method. Following the closings of the Exchange Transactions, $45 million in aggregate principal amount of the 2017 Notes remained outstanding, with the terms unchanged. 2017 Notes The 2017 Notes bear interest at a fixed rate of 5.00% per year, payable semiannually in arrears on April 1 and October 1 of each year. The 2017 Notes mature on October 1, 2017 , unless earlier converted, redeemed, or repurchased. The 2017 Notes are convertible at any time prior to the third trading day immediately preceding the maturity date, at the option of the holders, into shares of common stock. The 2017 Notes are convertible into a total of 9.7 million shares of common stock, which was equal to an initial conversion rate of 216.0644 shares of common stock per $1,000 principal amount of the 2017 Notes (equivalent to an initial conversion price of approximately $4.63 per share of common stock), and will be subject to adjustment upon the occurrence of certain events. The maximum conversion rate is 275.4821 shares of common stock per $1,000 principal amount of the 2017 Notes, which would result in a maximum issuance of 12.4 million shares of common stock if all holders converted at the maximum conversion rate. In addition, under certain circumstances the Company, in connection with a make-whole fundamental change (as defined in the indenture governing the 2017 Notes), may be required to increase the conversion rate for holders of the 2017 Notes. As of September 30, 2015 , no change to the conversion rate has occurred on the 2017 Notes. The Company may not redeem the 2017 Notes prior to October 1, 2015 . On or after October 1, 2015 , the Company may redeem for cash all, but not less than all, of the 2017 Notes if the last reported sale price of the common stock equals or exceeds 140% of the applicable conversion price for at least 20 trading days during the 30 consecutive trading day period ending on the trading day immediately prior to the date on which the notice of the redemption is delivered. The redemption price will equal 100% of the principal amount of the 2017 Notes to be redeemed, plus any accrued and unpaid interest to, but excluding, the redemption date. In addition, if the 2017 Notes are called for redemption, a make-whole fundamental change will be deemed to occur. As a result, in certain circumstances, this would increase the conversion rate for holders who convert their 2017 Notes after a notice of redemption is delivered and on or prior to the close of business on the third business day immediately preceding the relevant redemption date. Upon a fundamental change, subject to certain exceptions, the holders may require that the Company repurchase some or all of their 2017 Notes for cash at a repurchase price equal to 100% of the principal amount of the 2017 Notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. On September 17, 2012, the Company entered into an indenture with Wells Fargo Bank, National Association, as trustee, relating to the 2017 Notes. The 2017 Notes are senior, unsecured obligations and rank equal in right of payment with existing and future senior, unsecured indebtedness, and will be senior in right of payment to any future indebtedness that is expressly subordinated to the 2017 Notes. The 2017 Notes will be effectively subordinated to existing and future secured indebtedness to the extent of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities and commitments of subsidiaries, including trade payables and any guarantees that they may provide with respect to any existing or future indebtedness. 2018 Notes The 2018 Notes bear interest at a fixed rate of 5.00% per year, payable semiannually in arrears on April 1 and October 1 of each year, beginning October 1, 2015 . Interest on the New Notes accrues from April 1, 2015 . The 2018 Notes will mature on January 1, 2018 , unless earlier converted or repurchased. The 2018 Notes are convertible at any time prior to the third trading day immediately preceding the maturity date, at the option of the holders, into shares of the Company’s common stock. Subject to compliance with certain conditions, the Company has the right to mandatorily convert the 2018 Notes if the last reported sales price of the Company's common stock is equal to or greater than 115% of the applicable conversion price of the 2018 Notes for at least 20 trading days during the 30 consecutive trading day period ending within five trading days immediately prior to the date on which the Company delivers a mandatory conversion notice. The conversion rate is initially 216.0644 shares of common stock per $1,000 principal amount of 2018 Notes (equivalent to an initial conversion price of approximately $4.63 per share of common stock), and will be subject to adjustment upon the occurrence of certain events. In addition, holders of the 2018 Notes who convert their 2018 Notes in connection with a make-whole fundamental change (defined in the indenture governing the 2018 Notes (the "Indenture")), whose 2018 Notes are converted in connection with a mandatory conversion or who convert their 2018 Notes on a conversion date on which the last reported sales price of the Company's common stock equals or exceeds the then applicable conversion price are, under certain circumstances, entitled to an increase in the conversion rate. The Company may not redeem the 2018 Notes prior to the maturity date. Upon a fundamental change (defined in the Indenture), subject to certain exceptions, the holders of the 2018 Notes may require that the Company repurchase some or all of their 2018 Notes for cash at a repurchase price equal to 100% of the principal amount of the 2018 Notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The 2018 Notes will be the Company’s senior, unsecured obligations and rank equal in right of payment with the Company’s existing and future senior, unsecured indebtedness, including the 2017 Notes, and will be senior in right of payment to any future indebtedness that is expressly subordinated to the 2018 Notes. The 2018 Notes will be effectively subordinated to the Company’s existing and future secured indebtedness to the extent of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities and commitments of the Company’s subsidiaries, including trade payables and any guarantees that they may provide with respect to any of the Company’s existing or future indebtedness. Bank Loans In May 2011, the Company entered into a Loan and Security Agreement (the "Loan Agreement") with Silicon Valley Bank, or SVB, that allowed for term loans of up to $20.0 million to be borrowed through August 31, 2012 , revolving cash borrowings of up to $10.0 million , as well as letters of credit all under a secured credit facility. All borrowings under the Loan Agreement were secured by substantially all of the Company's assets, except for intellectual property, and were subject to certain other exceptions. The Loan Agreement included limitations on the ability, among other things, to incur debt, to grant liens, to make certain investments, to make certain restricted payments such as dividend payments, and to dispose of assets, as well as requirements to meet a number of affirmative and negative covenants. The Company borrowed under the term loans $5.0 million and $15.0 million during the years ended December 31, 2012 and 2011, respectively. Under the Loan Agreement, the term loans had accrued interest at the rate fixed on the date of funding equal to the U.S. treasury rate plus 3.25% per annum. The term loan borrowings were being repaid in 33 equal installments of principal, plus accrued interest which commenced on September 1, 2012 . The final payment on the term loans of $1.3 million was made on the loan maturity date, May 1, 2015 , and included a final payment of 3.5% of all advances made under the term loans, in addition to principal repayments. Obligation for Building and Improvements In November 2011, the Company entered into a lease agreement for a building in Raleigh-Durham, North Carolina, that is accounted for as a financing lease. The term of the lease and the obligation was initially 15 years through October 2026, including two 2 -year extensions of the lease. Rent payments under the lease are allocated primarily between interest expense and a reduction to the long-term obligation. In the event the lease is terminated prior to the end of the 15 -year period, any gain representing the amount by which the balance of the obligation exceeds the net book value of the related building and improvements would be recognized.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Ariosa Litigation In December 2011, the Company was named as a defendant in a complaint filed by plaintiff Aria Diagnostics, Inc., in the U.S. District Court for the Northern District of California ("District Court"). Since the complaint was filed, Aria changed its name to Ariosa Diagnostics, Inc., or Ariosa. In the complaint, the plaintiff seeks a judicial declaration that no activities related to the plaintiff's noninvasive, prenatal test using cell-free DNA circulating in the blood of a pregnant woman do or will infringe any claim of U.S Patent No. 6,258,540 entitled Noninvasive Prenatal Diagnosis, or the '540 Patent, which was exclusively in-licensed from Isis prior to September 30, 2014 when the Company purchased the patent from Isis. In March 2012, the Company filed an answer to the complaint and asserted counterclaims that Ariosa is infringing the '540 Patent and seeking unspecified damages and injunctive relief. In March 2012, Ariosa responded to the Company's answer and counterclaims and asserted affirmative defenses including invalidity of the '540 Patent under U.S. patent laws. In March 2012, the Company filed a motion against Ariosa for preliminary injunctive relief. On July 5, 2012, the Court denied the Company's motion for preliminary injunctive relief and on July 16, 2012 the Company filed a Notice of Appeal to the U.S. Court of Appeals for the Federal Circuit ("CAFC") from the order denying the preliminary injunction motion. On August 9, 2013, the CAFC vacated and remanded the District Court’s decision, ruling that the District Court incorrectly interpreted the claims of the '540 patent and improperly balanced factors regarding issuance of a preliminary injunction. On August 16, 2013, Ariosa filed a motion for summary judgment in favor of Ariosa on the Company's counterclaim for patent infringement on the ground that the claims of the '540 Patent are invalid because they are not drawn to patent-eligible subject matter under the patent code. On October 16, 2013, the District Court issued its order on the interpretation of the claims of the patent. On October 30, 2013, the District Court issued its order granting Ariosa’s motion for summary judgment, finding that the '540 Patent is invalid. The Company disagrees with the Order and has appealed the decision to the CAFC. On June 12, 2015, a three-judge panel of the CAFC upheld the ruling of the District Court that the claims of the '540 patent are not patent eligible under the patent eligibility criteria established by the United States Supreme Court's Mayo Collaborative Services v. Prometheus Laboratories decision. On July 7, 2015, the Company filed a motion to extend the deadline to file a petition for a rehearing en banc at the CAFC to August 13, 2015. On July 13, 2015, the CAFC granted the petition to extend the deadline to August 13, 2015. On August 13, 2015, the Company filed its petition for rehearing en banc at the CAFC. From August 25, 2015 through August 27, 2015, thirteen separate organizations, individuals and groups of individuals filed separate briefs of amicus curiae in support of the Company's petition for rehearing en banc . On October 19, 2015, Ariosa filed a response to the Company's petition for rehearing en banc urging the CAFC to deny the Company's petition for rehearing. If the CAFC elects to rehear the case and overturns the panel's decision, the Company intends to vigorously defend against the judicial declarations sought by Ariosa in its complaint and intends to vigorously pursue the Company's claims against Ariosa for damages and injunctive relief. However, the Company cannot predict the outcome of this matter. Ariosa Inter Partes Review In addition, Ariosa has sought to invalidate the '540 Patent through a petition for inter parties review ("IPR") before the Patent Trial and Appeal Board ("PTAB") of the United States Patent and Trademark Office ("USPTO"). Trial of the IPR was held before the PTAB on January 24, 2014. The PTAB issued a Decision in the IPR on September 2, 2014 invalidating some claims but upholding the validity of other claims. Both the Company and Ariosa requested reconsideration of the PTAB decision. On March 24, 2015, the PTAB denied both parties’ requests for reconsideration. Ariosa has filed a notice of intention to appeal the PTAB decision to the CAFC and the Company filed a notice to appeal as well. In light of the CAFC decision in the Ariosa Litigation, on July 20, 2015, the Company and Ariosa jointly filed a petition to stay the appeal in the CAFC until any appeal in the Ariosa Litigation is finalized. The CAFC granted the petition to stay the appeal on July 22, 2015 and directed the parties to inform the CAFC within fourteen days of the final disposition of the Ariosa Litigation. Natera Litigation In January 2012, the Company was named as a defendant in a complaint filed by plaintiff Natera, a Delaware corporation, in the U.S. District Court for the Northern District of California ("District Court"). In the complaint, the plaintiff seeks a judicial declaration that (i) activities related to the plaintiff's noninvasive, prenatal paternity test do not directly or indirectly infringe any claim of the '540 Patent, and (ii) one or more claims of the '540 Patent are invalid for failure to comply with the requirements of the patent laws of the U.S. In April 2012, the Company filed an answer to the complaint and asserted counterclaims that Natera and DNA Diagnostics Center, Inc., or DDC, are infringing the '540 Patent based on their activities relating to noninvasive prenatal paternity testing and noninvasive prenatal aneuploidy testing and seeking unspecified damages and injunctive relief. On October 16, 2013, the District Court issued its order on the interpretation of the patent claims. Many of the '540 Patent claims asserted against Natera are the same claims that were invalidated by the District Court on October 30, 2013 in the litigation involving Ariosa, set forth above, and the Company and Natera stipulated to final judgment on the '540 patent claims in this case and have appealed the patent invalidity determination to the CAFC, which has consolidated the Ariosa, Natera, and Verinata case appeals. On June 12, 2015, a three-judge panel of t he CAFC upheld the ruling of the District Court that the claims of the '540 patent are not patent eligible under the patent eligibility criteria established by the United States Supreme Court's Mayo Collaborative Services v. Prometheus Laboratories decision. O n July 7, 2015, the Company filed a motion to extend the deadline to file a petition for a rehearing en banc at the CAFC to August 13, 2015. On July 13, 2015, the CAFC granted the petition to extend the deadline to August 13, 2015. On August 13, 2015, the Company filed its petition for rehearing en banc at the CAFC. From August 25, 2015 through August 27, 2015, thirteen separate organizations, individuals and groups of individuals filed separate briefs of amicus curiae in support of the Company’s petition for rehearing en banc. On October 19, 2015, Natera filed a response to the Company’s petition for rehearing en banc urging the CAFC to deny the Company’s petition for rehearing. If the CAFC elects to rehear the case and overturns the panel’s decision , the Company intends to vigorously defend against the judicial declarations sought by Natera in its complaint and intends to vigorously pursue the Company’s claims against Natera for damages and injunctive relief. However, the Company cannot predict the outcome of this matter. Verinata and Stanford Litigation In February 2012, the Company was named as a defendant in a complaint filed by plaintiffs and The Board of Trustees of the Leland Stanford Junior University, or Stanford, in the District Court. Verinata was acquired by Illumina in 2013. In the complaint (i) Verinata seeks a judicial declaration that activities related to its noninvasive prenatal test using cell-free DNA circulating in the blood of a pregnant woman do not directly or indirectly infringe any claim of the '540 Patent, which at the time was exclusively in-licensed from Isis but has since been purchased from Isis, (ii) Verinata seeks a judicial declaration that each claim of the '540 Patent is invalid for failure to comply with the requirements of the patent laws of the U.S., and (iii) Verinata and Stanford allege that the Company, by performing its noninvasive prenatal MaterniT21 test, has and continues to directly infringe U.S. Patents which have been exclusively licensed to Verinata by Stanford and seek unspecified damages. In March 2012, the Company filed an answer to the complaint and asserted counterclaims that Verinata is infringing the '540 Patent and seeking unspecified damages and injunctive relief. In June 2012, plaintiffs Verinata and Stanford amended their complaint and allege that the Company, by performing its noninvasive prenatal MaterniT21 PLUS test, has and continues to directly infringe on a patent which has been exclusively licensed to Verinata by Stanford and seek unspecified damages. In July 2012, the Company filed an answer to the complaint. On October 16, 2013, the District Court issued its order on the interpretation. Many of the '540 Patent claims asserted against Verinata are the same claims that were invalidated by the District Court on October 30, 2013 in the litigation involving Ariosa, set forth above, and the Company and Verinata stipulated to final judgment on the '540 patent claims in this case and have appealed the patent invalidity determination to the CAFC. The District Court set trial beginning February 23, 2015. On December 2, 2014, the Company and Verinata reached a settlement that resolved litigation between them, and all litigation between the Company and Verinata related to these patents is now dismissed. As part of that settlement, the patents and pending applications are now pooled under a Pooled Patents Agreement between the Company and Illumina (which acquired Verinata). The Company and Verinata are now licensees to the patent rights that are pooled under the Pooled Patents Agreement. Verinata Patent Interference I On March 12, 2013, the USPTO declared a patent interference between Verinata's patent, which Verinata had asserted against us in the litigation, and the Company's then in-licensed (from CUHK) pending patent application. Two related patent interferences were declared by the USPTO between patent applications related to the patent and application. On April 7, 2014, the USPTO concluded the interferences, ruling that Verinata’s patent lacked sufficient disclosure to meet the written description requirement for the patent claims, and entered judgment canceling all four of the patent claims in the interference and the involved claims of the related patent application. Verinata has appealed the USPTO’s decision to the District Court. The District Court had set trial beginning February 23, 2015 on the appeal but has stayed the trial indefinitely pending a decision by the CAFC that would resolve a jurisdictional issue. On December 2, 2014, the involved patents and applications were added to the patent pool. On August 27, 2015, the District Court transferred the appeal from the patent interference to the CAFC. On October 9, 2015, the CAFC issued an order that corrected the caption for the appeal to: The Board of Trustees of the Leland Stanford Junior University, Plaintiff-Appellant v. The Chinese University Hong Kong, Defendant-Appellee 2015-2011. The Company is not a party to the appeal. Verinata Patent Interference II On May 3, 2013, the USPTO declared a patent interference between Verinata's patent, which Verinata has asserted against us in the litigation, and the Company's then in-licensed (from CUHK) pending patent application. On April 7, 2014, the USPTO ruled that the pending patent application has sufficient disclosure to meet the written description requirement for the patent claims and ordered the interference to proceed to the priority phase to determine which inventors were the first to invent the subject matter of the interference and entitled to a patent on that subject matter. The Company also separately challenged the validity of Verinata’s Patent in an inter partes review proceeding before the USPTO. The USPTO recently issued a decision in the Interference and the patent IPR upholding the validity of the patent. Pursuant to the terms of its settlement with Verinata, the Company will not appeal these decisions. EU Opposition Proceedings On September 29, 2014 and October 1, 2014, two unknown third parties initiated Opposition Proceedings against a European Patent. This patent was previously in-licensed by the Company from CUHK but has since been added to the patent pool under the Pooled Patents Agreement. The Company has rights to this patent under the patent pool but no longer controls efforts to defend this patent in the Opposition Proceedings. Premaitha Litigation On March 13, 2015, Illumina and its wholly-owned subsidiary Verinata filed a patent infringement lawsuit against Premaitha Health (UK) ("Permaitha"). The lawsuit was filed in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom. The lawsuit alleges that Premaitha’s Iona test for fetal aneuploidy infringes two pooled patents: European Patent No. EP 0 994 963 B2, or (the “ ‘963 B2 Patent”) and European Patent No. EP 1 981 995 B1. The ‘963 B2 Patent is owned by the Company. The Company is named as a plaintiff and is participating in the lawsuit as the owner of the ‘963 B2 Patent. In its Defense and Counterclaim filed on April 29, 2015, Premaitha denies infringement and alleges that both asserted patents are invalid. On September 30, 2015, Illumina filed a second lawsuit alleging that Premaitha’s Iona test for fetal aneuploidy infringes a third pooled patent: European Patent No. EP 2 183 693 B1. The Company is not a party to this second lawsuit. Other In addition, from time to time, the Company may be involved in litigation, claims, investigations and/or proceedings relating to employment, intellectual property and contractual matters as well as claims arising out of the Company's operations in the normal course of business, including claims related to the Company's products, tests, and services, including LDT services. These other matters are, in the opinion of management, immaterial with respect to the Company's consolidated financial position, liquidity, or results of operations or the damage amounts alleged by claimants are not necessarily meaningful indicators of potential liabilities. The Company determines whether it should accrue an estimated loss for a contingency in a particular legal proceeding by assessing whether a loss is deemed probable and whether the amount can be reasonably estimated. Claim estimates that are probable and can be reasonably estimated are reflected as liabilities. Legal proceedings are inherently unpredictable and the matters in which the Company is involved often present complex legal and factual issues. Because of the uncertainties related to the Company's pending litigation, investigations, inquiries or claims, management is currently unable to predict the ultimate outcome of any litigation, investigation, inquiry or claim, determine whether a liability has been incurred, or make an estimate regarding the possible loss or range of loss that could result from an unfavorable outcome. It is reasonably possible that some of the matters, which are pending or may be asserted, could be decided unfavorably to us. An adverse ruling or outcome in any lawsuit involving us could materially affect the Company's business, liquidity, consolidated financial position or results of operations, the ability to sell one or more of the Company's products or could result in additional competition. In view of the unpredictable nature of such matters, the Company cannot provide any assurances regarding the outcome of any litigation, investigation, inquiry or claim to which the Company is a party or the impact on us of an adverse ruling of such matters.

Stock Compensation Plans

Stock Compensation Plans	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Compensation Plans	Stock Compensation Plans Equity Incentive Plans The following table summarizes stock option activity of the Company during the nine months ended September 30, 2015 : Shares Subject to Options (in thousands) Weighted-Average Exercise Price per Share As of December 31, 2014 11,116 $4.96 Granted 1,878 $3.58 Exercised (267) $2.46 Forfeitures and cancellations (1,454) $4.39 Outstanding at September 30, 2015 11,273 $4.86 Options exercisable at September 30, 2015 8,428 $5.35 The following table summarizes activity related to restricted stock awards and restricted stock units of the Company during the nine months ended September 30, 2015 : Number of Shares (in thousands) Weighted-Average Outstanding at December 31, 2014 1,674 $2.99 Grants and awards 1,336 $3.53 Vested and released (617) $2.94 Forfeitures and cancellations (592) $3.20 Outstanding at September 30, 2015 1,801 $3.34 Issuances of Common Stock In the nine months ended September 30, 2015 , the Company issued a total of 348,726 shares of common stock under the employee stock purchase plan (the "ESPP") and 266,681 shares from the exercise of stock options, resulting in proceeds of $1.6 million . Stock-Based Compensation Expense Following are the weighted-average underlying assumptions used to determine the fair value of stock option award grants and for stock purchase rights under the ESPP for the periods indicated: Nine Months Ended September 30, Stock Option Grants 2015 2014 Risk-free interest rate 1.8 % 2.0 % Volatility 91.8 % 94.0 % Dividend yield — % — % Expected life (years) 7.2 7.1 Weighted-average grant date fair value $ 2.84 $ 2.01 Nine Months Ended September 30, ESPP Stock Purchase Rights 2015 2014 Risk-free interest rate 0.99 % 0.08 % Volatility 74.2 % 62.0 % Dividend yield — % — % Expected life (years) 0.5 0.5 Weighted-average grant date fair value $ 1.08 $ 0.85

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Assets and Liabilities Measured at Fair Value on a Recurring Basis The following tables summarize the fair value hierarchy for assets and liabilities measured at fair value on a recurring basis (in thousands): Fair Value Measurements at Reporting Date Using As of September 30, 2015 Fair Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Cash equivalents: Money market funds $ 42,350 $ 42,350 $ — Total cash equivalents 42,350 42,350 — Marketable securities: U.S. treasury securities 30,194 30,194 — Certificates of deposit 50 — 50 Mutual funds 492 492 — Total marketable securities 30,736 30,686 50 Total $ 73,086 $ 73,036 $ 50 Fair Value Measurements at Reporting Date Using As of December 31, 2014 Fair Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Cash equivalents: Money market funds $ 50,359 $ 50,359 $ — Total cash equivalents 50,359 50,359 — Marketable securities: U.S. treasury securities 30,020 30,020 — Certificates of deposit 48 — 48 Mutual funds 520 520 — Total marketable securities 30,588 30,540 48 Total $ 80,947 $ 80,899 $ 48 There were no transfers in or out of Level 1, Level 2, or Level 3 investments during the nine months ended September 30, 2015 . For fair values determined by Level 1 inputs, which utilize quoted prices in active markets for identical assets, the level of judgment required to estimate fair value is relatively low. The value of investments in money market funds, U.S. treasury securities and mutual funds was determined using Level 1 inputs. Fair values determined by Level 2 inputs, which utilize data points that are observable such as quoted prices, interest rates and yield curves. Investments in certificates of deposit are valued using Level 2 inputs. Fair Value of Other Financial Instruments The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts payable and accrued expenses, approximate fair value due to their short-term nature. The carrying amounts and fair values the 2017 Notes and 2018 Notes are as follows (in thousands): September 30, 2015 December 31, 2014 Carrying Amount Fair Value Carrying Amount Fair Value Convertible Senior Notes $ 129,031 $ 111,918 $ 130,000 $ 134,227 At September 30, 2015 and December 31, 2014 , the fair values of the Notes were based on quoted market prices in an active market for the Notes (Level 1).

Restructuring Costs

Restructuring Costs	9 Months Ended
	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
Restructuring Charges	Restructuring Costs and Other Charges Restructuring costs and other charges consisted of the following (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Impairment of property and equipment $ — $ — $ 386 $ — Employee termination cost — — 270 (29 ) Facility exit costs — — — 1,914 Restructuring costs and other charges $ — $ — $ 656 $ 1,885 As part of an overall cost reduction effort, in August 2013 , the Company exited a leased facility in San Diego, California, which was available for sublease until the lease expired in July 2015 . In connection with the restructuring, the Company recorded $2.4 million in facility exit costs, and $1.7 million of impairment expense for tenant improvements associated with the vacated facility, in addition to other restructuring charges during the year ended December 31, 2013. In 2014, based on the shortened period where the facility could be subleased and in consideration of other new information, management reassessed the remaining liabilities in connection with the restructuring and recorded an additional $1.9 million of restructuring expense related to the vacated facility. The restructuring cost is for the lease obligation and costs to operate the facility through the lease expiration date in July 2015. In May 2015, the Company decommissioned one of its research and development laboratories as part of the Company's plan to move certain general and administrative functions into the Company's corporate headquarters facility. As part of the decommissioning of the laboratory the Company recognized an impairment charge of $ 0.4 million on certain laboratory assets which it deemed would no longer be used. Additionally, in May 2015, the Company committed to a plan to consolidate its Grand Rapids facility to its facility located in North Carolina. In connection with the plan the Company recognized $0.3 million in employee terminations costs during the nine months ended September 30, 2015. The following table provides a rollforward of the amounts recorded as liabilities within the condensed consolidated balance sheet (in thousands): December 31, 2014 Accruals Payments September 30, 2015 Employee termination costs $ — $ 270 $ (270 ) $ — Facility exits costs 1,195 — (1,195 ) — Total $ 1,195 $ 270 $ (1,465 ) $ —

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company’s income tax expense is primarily due to tax liabilities resulting from state operations and deferred income tax expense related to amortization of indefinite lived intangibles. The Company’s income tax expense is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. A valuation allowance is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction by jurisdiction basis, and includes a review of all available positive and negative evidence. When the Company establishes or reduces the valuation allowance against deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. As of September 30, 2015 and December 31, 2014, the Company maintained valuation allowances against its deferred tax assets as the Company concluded it had not met the “more likely than not” threshold. Changes in the valuation allowance when they are recognized in the provision for income taxes may result in a change in the estimated annual effective tax rate.

Other Transactions Other Transa

Other Transactions Other Transactions	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Other Transactions	On August 3, 2015, Sequenom Laboratories entered into an Asset Purchase Agreement with Immucor GTI Diagnostics, Inc. ("Immucor") pursuant to which Sequenom Laboratories sold certain assets and assigned certain agreements relating to the Grand Rapids facilities to Immucor effective August 3, 2015. In consideration for the transferred assets, Sequenom Laboratories received a one-time cash payment of $0.8 million .

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation The accompanying unaudited condensed consolidated financial statements of Sequenom, Inc. should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 , as filed with the Securities and Exchange Commission. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the interim statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements, which include all wholly owned subsidiaries, reflect all adjustments, consisting of normal recurring adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. Interim results are not necessarily indicative of results for a full year or any other period(s). Reclassifications Certain amounts previously reported have been reclassified to conform to the current period presentation. The reclassification was made to change the statements of operations and comprehensive loss presentation to provide the users of the financial statements additional information related to the revenues of the Company. The reclassification included reclassifying amounts previously included in diagnostic services revenue to license revenue. The reclassification had no effect on consolidated net earnings or consolidated assets and liabilities. Segment and Geographic Information The Company evaluates segment reporting in accordance with Accounting Standards Codification ("ASC") 280 during each reporting period, including evaluating the reporting package reviewed by the Company’s Chief Operating Decision Maker (the "CODM"). As of September 30, 2015, the Company concluded it operates in a single operating segment and a single reporting unit as a provider of innovative diagnostic testing services based on the financial information available and that is evaluated regularly by the CODM in deciding how to allocate resources and in assessing performance. The Company derives its diagnostic services revenue from domestic and international customers by providing testing services in its laboratories located in San Diego, California and Raleigh-Durham, North Carolina. During the three and nine months ended September 30, 2015, 5% of diagnostic services revenue was recognized from international customers. During the three and nine months ended September 30, 2014, 13% of diagnostic services revenue was recognized from international customers. The Company also generates license revenue through the Company's Pooled Patents Agreement (the "Pooled Patents Agreement") with Illumina, Inc. ("Illumina"). The Company has limited visibility into the revenue reported by Illumina to the Company. For the portion of the Company's license revenue recognized from the Pooled Patents Agreement that is derived from Illumina partners or licensees, the Company does not have the ability to determine whether the license revenue was derived from domestic or international sources. Discontinued Operations On May 30, 2014, the Company sold its Bioscience business segment. As a result of the sale, the Company's Bioscience segment has been excluded from continuing operations for all periods herein and reported as discontinued operations. For additional information on the divestiture of the Company's Bioscience segment, see Note 3, Discontinued Operations. Revenue Recognition The Company generates revenue from diagnostic services from providing laboratory-developed tests ("LDTs"), primarily for the detection of specific fetal abnormalities or other genetic conditions, as well as through the Pooled Patents Agreement and others who have licensed the Company's technology. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. The Company assesses whether the fee is fixed or determinable based on the nature of the fee charged for the services delivered, whether there are existing contractual arrangements, and historical payment patterns. In determining when to record revenue, the Company evaluates collectability and considers whether there is sufficient history to reliably estimate a payor's payment patterns. Revenue is deferred for fees received before earned. Diagnostic service revenues are derived from providing testing services in the Company's laboratory, which are reimbursed through arrangements with third-party payors and amounts patients self-pay or through contractual arrangements (client bill). Diagnostic services revenue for third-party payors is recognized upon cash collection until a reliable estimate of the amount that would be ultimately collected for the test and the above criteria have been met, at which time revenue is recognized on an accrual basis. Third-party payors include commercial payors, such as health insurance companies, health maintenance organizations and government payors, such as Medicare and Medicaid in the United States. Client bill revenue is primarily recognized on an accrual basis and includes laboratories and customers with whom the Company has a contractual agreement where they will pay for the test upon delivery of the test results to the ordering physicians. The Company generally bills third-party payors upon delivery of a test result to the ordering physician following completion of a test. Patients have responsibility for out-of-pocket costs for amounts not covered by their insurance carrier and the Company bills the patient directly for these amounts in the form of co-pays and deductibles in accordance with their insurance carrier and health plans. Revenue from patients, through co-payments or through cash based service offerings, are recognized on a cash basis. Some payors may not cover the test as ordered by the physician under their reimbursement policies. Consequently, the Company pursues reimbursement on a case-by-case basis. From time to time, the Company receives requests for refunds of payments, generally due to overpayments made by third-party payors. Upon becoming aware of a refund request, the Company establishes an accrued liability for tests covered by the refund request until such time as the Company determines whether or not a refund is due. License arrangements with third-party partners may involve multiple elements and the Company evaluates the agreements to determine whether each deliverable represents a separate unit of accounting. A deliverable constitutes a separate unit of accounting when it has stand-alone value to the customer. Items are considered to have stand-alone value when they are sold separately by any vendor or when the customer could resell the item on a stand-alone basis. Consideration is allocated at the inception of the contract to all deliverables based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence ("VSOE") of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence exists, the Company uses its best estimate of the selling price for the deliverable. Such amounts are recognized as revenue when each unit is delivered. If the delivered element does not have stand-alone value without one of the undelivered elements in the arrangement, the elements are combined and accounted for as a single unit of accounting. Such amounts are recognized as revenue when the last deliverable of the combined units is delivered. Recurring revenue generated under license or royalty arrangements, including the Pooled Patents Agreement with Illumina, is recognized in the period reported by the partner or licensee and when the revenue recognition criteria have been met.
Cost of Revenue	Cost of Revenues Cost of revenues include the cost of materials, direct labor (including laboratory and service personnel), equipment and infrastructure expenses associated with processing blood and other samples, quality control analyses, shipping charges to transport samples, and license and test fees, including those owed to Illumina as specified in the Pooled Patents Agreement. Infrastructure expenses include allocated facility occupancy and information technology costs. Costs associated with performing testing services are recorded as tests are processed. Costs recorded for sample processing and shipping charges represent the cost of all the tests processed during the period regardless of whether revenue is recognized with respect to that test. Royalties for licensed technology calculated on a per test basis or as a percentage of product revenue and fixed annual payments relating to the launch and commercialization of LDTs are recorded as license fees in cost of revenues at the time product revenue is recognized or in accordance with other contractual obligations.
Pooled Patents Agreement	Pooled Patents Agreement On December 2, 2014, the Company entered into the Pooled Patents Agreement with Illumina, pursuant to which the parties pooled their intellectual property directed to noninvasive prenatal testing ("NIPT"). In accordance with the Pooled Patents Agreement, Sequenom, Inc. and the Chinese University of Hong Kong ("CUHK") entered into an agreement (the "CUHK Agreement"), pursuant to which certain license agreements by and between the Company and CUHK were amended and assigned to Illumina for inclusion in the patent pool, subject to the Pooled Patents Agreement. Illumina is responsible for paying all royalties to CUHK under the CUHK license agreements, and granted the Company a sublicense under each agreement to exploit laboratory-developed NIPT tests in accordance with the Pooled Patents Agreement. In connection with entering into the Pooled Patents Agreement, the Company also entered into an Amended and Restated Sale and Supply Agreement with Illumina (the "Supply Agreement"), pursuant to which the Company and its affiliates purchase various products from Illumina for use in NIPT as well as for other clinical and research uses. Concurrently, with the execution of the Pooled Patents Agreement, the Company, Illumina, Sequenom Center for Molecular Medicine, LLC ("SCMM" a subsidiary of Sequenom Inc.), and Verinata Health, Inc., (“Verinata ” a subsidiary of Illumina) entered into a Settlement Agreement (the "Settlement Agreement"), pursuant to which the parties settled certain claims and released the other parties from potential liability. The Company determined that the Pooled Patents Agreement, the Settlement Agreement, the Supply Agreement and the CUHK Agreement were all part of a single transaction with multiple elements as the various agreements were contemporaneously negotiated, contingent upon one another and negotiated with the same counterparties. As the agreements were considered to be part of one transaction with multiple elements, the Company followed the accounting guidance in ASC 605-25 to determine the separate units of account and the basis for allocating the consideration received. The Company evaluated all elements of the agreements and identified the following deliverables that had value; (1) the physical samples and applicable study protocols, (2) transfer of in vitro diagnostic, or IVD, technology (3) settlement of claims and disputes between the Company and Illumina and (4) the $6.15 million upfront payment made to CUHK. The Company allocated consideration to the physical samples and transfer of IVD technology based on its best estimate of selling price for each of the deliverables, which were derived from the Company's models as well as through the use of a third-party valuation expert. The physical samples and applicable study protocols were valued using the cost to recreate method, a form of the cost approach. The key inputs and assumptions used in this model included historical clinical study cost for gathering each sample plus a premium applied to the historical costs. The IVD technology was valued using the differential cash flow method, a form of the income approach. The key inputs and assumptions used in this model included forecasted IVD revenues and estimated royalties rates. The Company determined the value to be allocated to the settlement of claims and disputes based on the residual value method due to the complex nature of the litigation and the inability to make a reliable estimate of value for this component. Consideration allocated to each element was $21.0 million for each of (i) the physical samples and (ii) the transfer of IVD technology, and $1.85 million for the settlement of claims and disputes. The $6.15 million payment made by the Company to CUHK was reflected as a reduction of the proceeds received from Illumina as this was primarily for the amendment of certain license agreements by and between the Company and CUHK, and the assignment of those agreements to Illumina for inclusion in the patent pool, and resulted in net consideration to be allocated by the Company of $43.85 million . At December 31, 2014 , the Company had recorded a $21.0 million deferred gain on the Pooled Patents Agreement, which was recognized as a gain during the three months ended March 31, 2015 following delivery and acceptance of the study related documents associated with the physical samples provided to Illumina.
Concentration of Risks	Concentration of Risks Financial instruments, which potentially are a concentration of credit risk, consist primarily of cash equivalents, marketable securities, and accounts receivable. The exposure to credit loss is limited by placing cash, cash equivalents and marketable securities with US financial institutions. Additionally, the Company has established guidelines regarding diversification of investments and their maturities, which are designed to maintain principal and maximize liquidity. Credit risk with respect to accounts receivable is limited due to the Company's large and diverse customer base. One customer represented more than 10% of total revenue during the three and nine months ended September 30, 2015, accounting for $3.1 million , or 10.3% , and $10.1 million , or 10.0% , of total revenue, respectively. One customer represented more than 10% of total revenue during the three and nine months ended September 30, 2014, accounting for $4.5 million , or 11.9% , and $17.3 million , or 15.1% , of total revenue, respectively. The Company requires raw materials and devices of appropriate quality and reliability and to meet applicable regulatory requirements that currently are available from a limited number of sources and in certain cases a single source of supply. Consequently, in the event that supplies are delayed or interrupted for any reason, it could impair the Company's ability to develop and produce services, which could have a material adverse effect on the Company's business, financial condition and results of operations.
Net Earnings (Loss) Per Share	Net Loss Per Share Basic and diluted net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Common stock equivalents that could potentially reduce net earnings per common share in the future that were not included in the determination of diluted net loss per common share as their effects were antidilutive are as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Shares underlying Convertible Senior Notes 28,088 28,088 28,088 28,088 Options to purchase common stock 10,612 12,906 10,510 13,688 Restricted stock units not yet vested and released 2,312 1,877 3,038 2,146 Warrants to purchase common stock 200 250 200 250 Total 41,212 43,121 41,836 44,172
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued an accounting standards update that creates a single source of revenue guidance for companies in all industries. The new standard provides guidance for all revenue arising from contracts with customers and affects all entities that enter into contracts to provide goods or services to their customers, unless the contracts are within the scope of other accounting standards. It also provides a model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets. This guidance, as amended, must be adopted using either a full retrospective approach for all periods presented or a modified retrospective approach and will be effective for fiscal years beginning after December 15, 2017, which will be the Company's fiscal year 2018. The Company has not yet evaluated the potential impact of adopting the guidance on the Company's consolidated financial statements. In April 2015, the FASB issued Accounting Standard Update ("ASU") No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs . The ASU is the result of the FASB's simplification initiative intended to improve GAAP by reducing costs and complexity while maintaining or enhancing the usefulness of related financial statement information. The ASU specifies that debt issuance costs related to a note shall be reported in the balance sheet as a direct reduction from the face amount of the note. The ASU is effective for interim and annual periods beginning on or after January 1, 2016. The ASU will require the Company to reclassify its capitalized debt issuance costs currently recorded as assets on the condensed consolidated balance sheets. The ASU will have no effect on the Company's results of operations or liquidity.

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Common stock equivalents that could potentially reduce net earnings per common share in the future that were not included in the determination of diluted net loss per common share as their effects were antidilutive are as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Shares underlying Convertible Senior Notes 28,088 28,088 28,088 28,088 Options to purchase common stock 10,612 12,906 10,510 13,688 Restricted stock units not yet vested and released 2,312 1,877 3,038 2,146 Warrants to purchase common stock 200 250 200 250 Total 41,212 43,121 41,836 44,172

Supplementary Financial Infor18

Supplementary Financial Information (Tables)	9 Months Ended
	Sep. 30, 2015
Other Financial Information [Abstract]
Marketable Securities	Marketable Securities, Available-for-sale (in thousands): September 30, 2015 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value U.S. treasury securities $ 30,185 $ 9 $ — $ 30,194 Certificates of deposit 50 — — 50 Mutual funds 282 210 — 492 Total marketable securities $ 30,517 $ 219 $ — $ 30,736 December 31, 2014 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value U.S. treasury securities $ 30,049 $ — $ (29 ) $ 30,020 Certificates of deposit 48 — — 48 Mutual funds 277 243 — 520 Total marketable securities $ 30,374 $ 243 $ (29 ) $ 30,588
Other Assets	Other Current Assets and Prepaid Expenses (in thousands): September 30, December 31, Pooled patents agreement receivable $ — $ 6,000 Other 5,345 6,112 Total $ 5,345 $ 12,112
Inventories	Inventories (in thousands): September 30, December 31, Raw materials $ 4,280 $ 6,165 Work in process 282 351 Total $ 4,562 $ 6,516
Accrued Expenses	Accrued Expenses (in thousands): September 30, December 31, Accrued royalties, licenses, and collaboration payments $ 4,756 $ 7,223 Accrued compensation and related taxes 5,031 7,606 Accrued professional fees and consulting 439 1,872 Other 3,272 5,454 Total $ 13,498 $ 22,155

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2015
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures	Therefore, the results of operations from the Bioscience business segment do not necessarily reflect what the results of operations would have been had the business operated as a stand-alone entity. The Company completed the sale of the Biosciences segment on May 30, 2014. Nine Months Ended September 30, Discontinued Operations (in thousands) 2014 Revenues: Bioscience product sales and services $ 12,470 Cost of revenues: Cost of bioscience product sales and services 4,235 Gross margin 8,235 Operating expenses: Selling and marketing 6,237 Research and development 2,248 General and administrative 643 Restructuring costs 19 Total operating expenses 9,147 Loss from discontinued operations (912 ) Other income, net 81 Loss from discontinued operations before income taxes (831 ) Income tax benefit 248 Earnings from discontinued operations $ (583 )

Long-Term Obligations (Tables)

Long-Term Obligations (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	Long-Term Obligations (in thousands, except percentages): As of September 30, 2015 As of December 31, 2014 5.00% Convertible Senior Notes due October 2017 ($45,000) and January 2018 ($85,000), interest payable semi-annually in April and October $ 130,000 $ 130,000 Unamortized debt discount on Convertible Exchange Senior Notes due January 2018 (969 ) — Bank Loans due May 2015, principal and interest payable monthly, weighted-average effective interest rates of 5.5%, net of unamortized discount of $8 at December 31, 2014. — 3,722 Obligation for building and improvements, effective interest rate of 5.2% as of September 30, 2015 and December 31, 2014, expiring October 2026 5,667 5,868 Capital lease liabilities, expiring January 2016, net of unamortized discounts of $2 and $17 at September 30, 2015 and December 31, 2014, respectively 52 156 Total long-term obligations 134,750 139,746 Less current portion (346 ) (4,144 ) Non-current portion $ 134,404 $ 135,602

Stock Compensation Plans (Table

Stock Compensation Plans (Tables)	9 Months Ended
	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes stock option activity of the Company during the nine months ended September 30, 2015 : Shares Subject to Options (in thousands) Weighted-Average Exercise Price per Share As of December 31, 2014 11,116 $4.96 Granted 1,878 $3.58 Exercised (267) $2.46 Forfeitures and cancellations (1,454) $4.39 Outstanding at September 30, 2015 11,273 $4.86 Options exercisable at September 30, 2015 8,428 $5.35
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	The following table summarizes activity related to restricted stock awards and restricted stock units of the Company during the nine months ended September 30, 2015 : Number of Shares (in thousands) Weighted-Average Outstanding at December 31, 2014 1,674 $2.99 Grants and awards 1,336 $3.53 Vested and released (617) $2.94 Forfeitures and cancellations (592) $3.20 Outstanding at September 30, 2015 1,801 $3.34
Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	Following are the weighted-average underlying assumptions used to determine the fair value of stock option award grants and for stock purchase rights under the ESPP for the periods indicated: Nine Months Ended September 30, Stock Option Grants 2015 2014 Risk-free interest rate 1.8 % 2.0 % Volatility 91.8 % 94.0 % Dividend yield — % — % Expected life (years) 7.2 7.1 Weighted-average grant date fair value $ 2.84 $ 2.01
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions	Nine Months Ended September 30, ESPP Stock Purchase Rights 2015 2014 Risk-free interest rate 0.99 % 0.08 % Volatility 74.2 % 62.0 % Dividend yield — % — % Expected life (years) 0.5 0.5 Weighted-average grant date fair value $ 1.08 $ 0.85

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Summary of fair value for assets measured on recurring basis	The following tables summarize the fair value hierarchy for assets and liabilities measured at fair value on a recurring basis (in thousands): Fair Value Measurements at Reporting Date Using As of September 30, 2015 Fair Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Cash equivalents: Money market funds $ 42,350 $ 42,350 $ — Total cash equivalents 42,350 42,350 — Marketable securities: U.S. treasury securities 30,194 30,194 — Certificates of deposit 50 — 50 Mutual funds 492 492 — Total marketable securities 30,736 30,686 50 Total $ 73,086 $ 73,036 $ 50 Fair Value Measurements at Reporting Date Using As of December 31, 2014 Fair Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Cash equivalents: Money market funds $ 50,359 $ 50,359 $ — Total cash equivalents 50,359 50,359 — Marketable securities: U.S. treasury securities 30,020 30,020 — Certificates of deposit 48 — 48 Mutual funds 520 520 — Total marketable securities 30,588 30,540 48 Total $ 80,947 $ 80,899 $ 48
Carrying amounts and fair value of long-term obligations	The carrying amounts and fair values the 2017 Notes and 2018 Notes are as follows (in thousands): September 30, 2015 December 31, 2014 Carrying Amount Fair Value Carrying Amount Fair Value Convertible Senior Notes $ 129,031 $ 111,918 $ 130,000 $ 134,227

Restructuring Costs (Tables)

Restructuring Costs (Tables)	9 Months Ended
	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
Restructuring Costs and Other Charges	Restructuring costs and other charges consisted of the following (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Impairment of property and equipment $ — $ — $ 386 $ — Employee termination cost — — 270 (29 ) Facility exit costs — — — 1,914 Restructuring costs and other charges $ — $ — $ 656 $ 1,885
Schedule of Restructuring Reserve by Type of Cost	The following table provides a rollforward of the amounts recorded as liabilities within the condensed consolidated balance sheet (in thousands): December 31, 2014 Accruals Payments September 30, 2015 Employee termination costs $ — $ 270 $ (270 ) $ — Facility exits costs 1,195 — (1,195 ) — Total $ 1,195 $ 270 $ (1,465 ) $ —

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Narrative) (Details) $ in Thousands	Dec. 02, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)Customers	Sep. 30, 2014USD ($)Customers
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on pooled patents agreement and sale of assets				$ 21,000
Revenue Recognition, Multiple-deliverable Arrangements, Determination of Selling Price, Amount				21,723	$ 0
Revenues		$ 29,901	$ 37,937	$ 100,473	$ 114,780
Collaborative Arrangement | Chinese University of Hong Kong
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Collaborative Arrangement, Aggregate Consideration, Up-front Payment	$ 6,150
Revenue Recognition, Multiple-deliverable Arrangements, Determination of Selling Price, Amount	43,850
Physical Samples | Collaborative Arrangement | Chinese University of Hong Kong
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue Recognition, Multiple-deliverable Arrangements, Determination of Selling Price, Amount	21,000
Settlements Of Claims And Disputes | Collaborative Arrangement | Chinese University of Hong Kong
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue Recognition, Multiple-deliverable Arrangements, Determination of Selling Price, Amount	$ 1,850
Sales Revenue, Net | Customer Concentration Risk
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Concentration risk percentage		10.30%	11.90%	10.00%	15.10%
Concentration risk, number of customers | Customers				1	1
Revenues		$ 3,100	$ 4,500	$ 10,100	$ 17,300
Sales Revenue, Net | Customer Concentration Risk | Diagnostic Services | International Locations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Concentration risk percentage		5.00%	13.00%	5.00%	13.00%

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Net Earnings (Loss) Per Share) (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	41,212	43,121	41,836	44,172
Shares underlying Senior Convertible Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	28,088	28,088	28,088	28,088
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	10,612	12,906	10,510	13,688
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	2,312	1,877	3,038	2,146
Warrants to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	200	250	200	250

Supplementary Financial Infor26

Supplementary Financial Information (Marketable Securities) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 30,517	$ 30,374
Gross Unrealized Gains	219	243
Gross Unrealized Losses	0	(29)
Estimated Fair Value	30,736	30,588
U.S. treasury securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	30,185	30,049
Gross Unrealized Gains	9	0
Gross Unrealized Losses	0	(29)
Estimated Fair Value	30,194	30,020
Certificates of deposit
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	50	48
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	50	48
Mutual funds
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	282	277
Gross Unrealized Gains	210	243
Gross Unrealized Losses	0	0
Estimated Fair Value	$ 492	$ 520

Supplementary Financial Infor27

Supplementary Financial Information (Other Assets) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Pooled patents agreement receivable	$ 0	$ 6,000
Other	5,345	6,112
Total	$ 5,345	$ 12,112

Supplementary Financial Infor28

Supplementary Financial Information (Schedule of Inventory Table) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 4,280	$ 6,165
Work in process	282	351
Total	$ 4,562	$ 6,516

Supplementary Financial Infor29

Supplementary Financial Information (Accrued Expenses) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Accrued Expenses [Abstract]
Accrued royalties, licenses, and collaboration payments	$ 4,756	$ 7,223
Accrued compensation and related taxes	5,031	7,606
Accrued professional fees and consulting	439	1,872
Other	3,272	5,454
Total	$ 13,498	$ 22,155

Discontinued Operations (Narrat

Discontinued Operations (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Discontinued Operations and Disposal Groups [Abstract]
Company purchases of consumables and systems	$ 0.2	$ 0.3	$ 0.5	$ 0.4

Discontinued Operations (Discon

Discontinued Operations (Discontinued Operations: Revenue, Assets and Liabilities) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Operating expenses:
Earnings from discontinued operations	$ 0	$ 0	$ 0	$ 13,812
BioSciences
Revenues:
Bioscience product sales and services				12,470
Cost of revenues:
Cost of bioscience product sales and services				4,235
Gross margin				8,235
Operating expenses:
Selling and marketing				6,237
Research and development				2,248
General and administrative				643
Restructuring costs				19
Total operating expenses				9,147
Loss from discontinued operations				(912)
Other income, net				81
Loss from discontinued operations before income taxes				(831)
Income tax benefit				248
Earnings from discontinued operations				$ (583)

Long-Term Obligations (Long-Ter

Long-Term Obligations (Long-Term Obligations Schedule) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Jun. 30, 2015	Dec. 31, 2014	Sep. 17, 2012
Debt Instrument [Line Items]
Convertible senior notes interest rate	5.00%		5.00%
Long-term debt and capital lease obligations	$ 134,750		$ 139,746
Long-term Debt and Capital Lease Obligations, Current	(346)		(4,144)
Long-term Debt and Captial Lease Obligations Excluding Current Portion	134,404		$ 135,602
5% Convertible Senior Notes, Due October 2017
Debt Instrument [Line Items]
Interest Payable	$ 45,000
Senior Notes | 5% Convertible Senior Notes, Due October 2017
Debt Instrument [Line Items]
Convertible senior notes interest rate	5.00%		5.00%	5.00%
Unamortized debt discount	$ (969)		$ 0
Long-term debt and capital lease obligations	130,000		130,000
Senior Notes | Convertible Exchange Senior Notes, Due January 2018
Debt Instrument [Line Items]
Interest Payable	85,000
Convertible senior notes interest rate				5.00%
Notes Payable to Banks | Bank Loans, Due May 2015
Debt Instrument [Line Items]
Unamortized debt discount		$ 0	(8)
Long-term debt and capital lease obligations	$ 0		$ 3,722
Debt, Weighted Average Interest Rate	0.00%		5.50%
Capital Lease Obligations | Financed Capital Lease Obligations, Due October 2026
Debt Instrument [Line Items]
Long-term debt and capital lease obligations	$ 5,667		$ 5,868
Capital Lease Obligations | Capital Lease Obligations, Due January 2016
Debt Instrument [Line Items]
Unamortized debt discount	(2)		(17)
Long-term debt and capital lease obligations	$ 52		$ 156
Debt Instrument, Interest Rate, Effective Percentage	5.20%		5.20%

Long-Term Obligations (Narrativ

Long-Term Obligations (Narrative) (Details)	1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
	Nov. 30, 2011option	Sep. 30, 2015USD ($)	Sep. 30, 2015USD ($)Installmentsdshares	Dec. 31, 2012USD ($)	Dec. 31, 2011USD ($)	Jun. 30, 2015USD ($)$ / shares	Dec. 31, 2014USD ($)	Sep. 17, 2012	May. 31, 2011USD ($)
Debt Instrument [Line Items]
Long-term debt and capital lease obligations		$ 134,750,000	$ 134,750,000				$ 139,746,000
Payments of debt restructuring costs		1,600,000
Increase in fair value conversion option						$ 1,100,000
Remaining discount amortization period			30 months
Convertible senior notes		$ 129,031,000	$ 129,031,000				$ 130,000,000
Convertible senior notes interest rate		5.00%	5.00%				5.00%
Capital lease obligation term	15 years
Capital lease obligation, number of extension options | option	2
5% Convertible Senior Notes, Due October 2017
Debt Instrument [Line Items]
Interest Payable		$ 45,000,000	$ 45,000,000
Convertible Notes Payable
Debt Instrument [Line Items]
Latest convertible date			Oct. 1, 2017
Loan Agreement
Debt Instrument [Line Items]
Term loan maximum borrowing capacity									$ 20,000,000
Expiration date			Aug. 31, 2012
Proceeds from issuance of debt				$ 5,000,000	$ 15,000,000
Number of repayment installments | Installments			33
Repayments of Long-term Debt			$ 1,300,000
Maturity date			May 1, 2015
Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity									$ 10,000,000
Minimum Final Payment | Loan Agreement
Debt Instrument [Line Items]
Percentage fee on advances						3.50%
U.S. Treasury Rate | Loan Agreement
Debt Instrument [Line Items]
Basis spread on variable rate			3.25%
Senior Notes | 5% Convertible Senior Notes, Due October 2017
Debt Instrument [Line Items]
Long-term debt and capital lease obligations		130,000,000	$ 130,000,000				$ 130,000,000
Convertible senior notes		$ 85,000,000	$ 85,000,000
Convertible senior notes interest rate		5.00%	5.00%				5.00%	5.00%
Number of equity instruments | shares			9,722,898
Conversion price | $ / shares						$ 4.63
Earliest call date			Oct. 1, 2015
Stock price trigger, percent of sales must exceed conversion price			140.00%
Stock price trigger, trading days | d			20
Stock price trigger, consecutive trading day period prior to notice of redemption			30 days
Redemption price percentage			100.00%
Senior Notes | Convertible Exchange Senior Notes, Due January 2018
Debt Instrument [Line Items]
Interest Payable		$ 85,000,000	$ 85,000,000
Convertible senior notes interest rate								5.00%
Conversion price | $ / shares						$ 4.63
Stock price trigger, trading days | d			20
Stock price trigger, consecutive trading day period prior to notice of redemption			30 days
Redemption price percentage			100.00%
Senior Notes | Minimum | 5% Convertible Senior Notes, Due October 2017
Debt Instrument [Line Items]
Conversion ratio			216.0644
Senior Notes | Minimum | Convertible Exchange Senior Notes, Due January 2018
Debt Instrument [Line Items]
Conversion ratio			216.0644
Stock price trigger, percent of sales must exceed conversion price			115.00%
Senior Notes | Maximum | 5% Convertible Senior Notes, Due October 2017
Debt Instrument [Line Items]
Number of equity instruments | shares			12,396,695
Conversion ratio			275.4821

Stock Compensation Plans (Narra

Stock Compensation Plans (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares issued	118,527,914	117,434,000
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares issued	266,681
Employee Stock Purchase Plan | Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares issued	348,726
Proceeds from issuance of common stock	$ 1.6

Stock Compensation Plans (Combi

Stock Compensation Plans (Combined Activity) (Details) - Equity Incentive Plan - Stock Options - Common Stock shares in Thousands	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period (shares) | shares	11,116
Granted (shares) | shares	1,878
Exercised (shares) | shares	(267)
Forfeitures and cancelled (shares) | shares	(1,454)
Outstanding at end of period (shares) | shares	11,273
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of period (usd per share)	$ 4.96
Granted (usd per share)	3.58
Exercised (usd per share)	2.46
Forfeited and cancelled (usd per share)	4.39
Outstanding at end of period (usd per share)	$ 4.86
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options exercisable at end of period, Shares Subject to Options | shares	8,428
Options vested and exercisable at end of period, Weighted Average Exercise Price	$ 5.35

Stock Compensation Plans (Restr

Stock Compensation Plans (Restricted Stock and Restricted Stock Units) (Details) - Restricted Stock - Restricted Stock shares in Thousands	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Oustanding at Beginning of Period (shares) | shares	1,674
Grants and awards (shares) | shares	1,336
Vested and released (shares) | shares	(617)
Forfeitures and cancellations (shares) | shares	(592)
Oustanding at End of Period (shares) | shares	1,801
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Outstanding at December 31, 2014	$ 2.99
Grants and awards	3.53
Vested and released	2.94
Forfeitures and cancellations	3.20
Outstanding at September 30, 2015	$ 3.34

Stock Compensation Plans (Weigh

Stock Compensation Plans (Weighted-Average Underlying Assumptions Used) (Details) - Common Stock - $ / shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Equity Incentive Plan | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.80%	2.00%
Volatility	91.80%	94.00%
Dividend yield	0.00%	0.00%
Expected life (years)	7 years 1 month 25 days	7 years 1 month 21 days
Weighted-average grant date fair value	$ 2.84	$ 2.01
Employee Stock Purchase Plan | Employee stock purchase rights
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.99%	0.08%
Volatility	74.20%	62.00%
Dividend yield	0.00%	0.00%
Expected life (years)	6 months	6 months
Weighted-average grant date fair value	$ 1.08	$ 0.85

Fair Value Measurements (Fair V

Fair Value Measurements (Fair Value, Assets and Liabilities Measured on a Recurring Basis) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Marketable securities:
Total	$ 73,086	$ 80,947
Quoted Prices in Active Markets for Identical Assets (Level 1)
Marketable securities:
Total	73,036	80,899
Significant Other Observable Inputs (Level 2)
Marketable securities:
Total	50	48
Marketable Securities
Marketable securities:
U.S. treasury securities	30,194	30,020
Certificates of deposit	50	48
Mutual funds	492	520
Total marketable securities	30,736	30,588
Marketable Securities | Quoted Prices in Active Markets for Identical Assets (Level 1)
Marketable securities:
U.S. treasury securities	30,194	30,020
Certificates of deposit	0	0
Mutual funds	492	520
Total marketable securities	30,686	30,540
Marketable Securities | Significant Other Observable Inputs (Level 2)
Marketable securities:
U.S. treasury securities	0	0
Certificates of deposit	50	48
Mutual funds	0	0
Total marketable securities	50	48
Cash Equivalents
Cash equivalents:
Money market funds	42,350	50,359
Total cash equivalents	42,350	50,359
Cash Equivalents | Quoted Prices in Active Markets for Identical Assets (Level 1)
Cash equivalents:
Money market funds	42,350	50,359
Total cash equivalents	42,350	50,359
Cash Equivalents | Significant Other Observable Inputs (Level 2)
Cash equivalents:
Money market funds	0	0
Total cash equivalents	$ 0	$ 0

Fair Value Measurements (Fair39

Fair Value Measurements (Fair Value of Long-term Commitments) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Carrying (Reported) Amount, Fair Value Disclosure
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Convertible Senior Notes	$ 129,031	$ 130,000
Estimate of Fair Value, Fair Value Disclosure
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Convertible Senior Notes	$ 111,918	$ 134,227

Restructuring Costs (Restructur

Restructuring Costs (Restructuring Costs and Other Charges) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Restructuring and Related Activities [Abstract]
Impairment of property and equipment	$ 0	$ 0	$ 386	$ 0
Employee termination cost	0	0	270	(29)
Facility exit costs	0	0	0	1,914
Restructuring costs and other charges	$ 0	$ 0	$ 656	$ 1,885

Restructuring Costs (Narrative)

Restructuring Costs (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2013
Restructuring Cost and Reserve [Line Items]
Initiation date			Aug. 19, 2013
Lease expiration date			Jul. 31, 2015
Restructuring costs and other charges	$ 0	$ 0	$ 656	$ 1,885
Non-cash restructuring costs and other charges	$ 0	0	386	$ 0
Restructuring Reserve, Accruals			270
Facility exit costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs and other charges					$ 2,400
Change in previous estimates		$ 1,900
Restructuring Reserve, Accruals			0
Impairment of Tenant Improvements
Restructuring Cost and Reserve [Line Items]
Restructuring costs and other charges					$ 1,700
Employee termination costs
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accruals			$ 270

Restructuring Costs (Restruct42

Restructuring Costs (Restructuring Reserve Roll Forward) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Restructuring Reserve [Roll Forward]
Balance at beginning of the period	$ 1,195
Restructuring Reserve, Accruals	270
Restructuring Reserve, Payments	(1,465)
Balance at the end of the period	0
Employee termination costs
Restructuring Reserve [Roll Forward]
Balance at beginning of the period	0
Restructuring Reserve, Accruals	270
Restructuring Reserve, Payments	(270)
Balance at the end of the period	0
Facility exit costs
Restructuring Reserve [Roll Forward]
Balance at beginning of the period	1,195
Restructuring Reserve, Accruals	0
Restructuring Reserve, Payments	(1,195)
Balance at the end of the period	$ 0

Other Transactions (Details)

Other Transactions (Details) - USD ($) $ in Thousands	Aug. 03, 2015	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014
Business Acquisition [Line Items]
Proceeds from sale of assets			$ 750	$ 0
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations
Business Acquisition [Line Items]
Proceeds from sale of assets	$ 800
Gain on sale of assets		$ 800	$ 0